Transferrin saturation was expectedly lower in IBD patients (23 ± 11%) than in healthy participants (35 ± 8%), possibly because of factors such as malabsorption, reduced appetite, increased hepcidin synthesis during chronic inflammation, and bleeding. Here, TF is linked to inflammatory bowel disease.